Seagen Inc News and Headlines -

GuruFocus Articles Total 36
  • 1
  • 2

Investment company Candriam Luxembourg S.C.A. (Current Portfolio) buys Seagen Inc, Array Technologies Inc, Viatris Inc, Cogent Biosciences Inc, Eargo Inc, sells Seagen Inc, New Oriental Education & Technology Group Inc, Tiffany, Varonis Systems Inc, Norbord Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Candriam Luxembourg S.C.A.. As of 2021Q1, Candriam Luxembourg S.C.A. owns 792 stocks with a total value of $11.9 billion. These are the details of the buys and sells.
0 Views    insider    2021-04-29 16:38
White Plains, NY, based Investment company IBM Retirement Fund (Current Portfolio) buys Seagen Inc, Viatris Inc, Royalty Pharma PLC, Pinnacle Financial Partners Inc, Concentrix Corp, sells Viatris Inc, Seagen Inc, DuPont de Nemours Inc, Tiffany, Sarepta Therapeutics Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, IBM Retirement Fund. As of 2021Q1, IBM Retirement Fund owns 773 stocks with a total value of $1.4 billion. These are the details of the buys and sells.
0 Views    insider    2021-04-22 12:38
New York, NY, based Investment company Grandfield & Dodd, Llc (Current Portfolio) buys Seagen Inc, Lowe's Inc, BancorpSouth Bank, EOG Resources Inc, Equinix Inc, sells UnitedHealth Group Inc, Seagen Inc, BTC iShares MSCI USA Min Vol Factor ETF, Amdocs, Eaton Vance Corp during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Grandfield & Dodd, Llc. As of 2021Q1, Grandfield & Dodd, Llc owns 197 stocks with a total value of $1.3 billion. These are the details of the buys and sells.
0 Views    insider    2021-04-22 12:38
Investment company Pioneer Trust Bank N A (Current Portfolio) buys Seagen Inc, FS KKR Capital Corp II, Aon PLC, Baxter International Inc, Crown Castle International Corp, sells Seagen Inc, Alphabet Inc, Becton, Dickinson and Co, Biogen Inc, Pfizer Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Pioneer Trust Bank N A. As of 2021Q1, Pioneer Trust Bank N A owns 74 stocks with a total value of $350 million. These are the details of the buys and sells.
0 Views    insider    2021-04-15 20:38
Philadelphia, PA, based Investment company Addison Capital Co (Current Portfolio) buys Rent-A-Center Inc, Seagen Inc, International Flavors & Fragrances Inc, Enterprise Products Partners LP, Applied Materials Inc, sells Seagen Inc, DuPont de Nemours Inc, Blackrock Municipal Income Trust, Barrick Gold Corp, Black Hills Corp during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Addison Capital Co. As of 2021Q1, Addison Capital Co owns 112 stocks with a total value of $180 million. These are the details of the buys and sells.
0 Views    insider    2021-04-12 16:38

President and CEO of Seagen Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 29,353 shares of SGEN on 04/09/2021 at an average price of $143.79 a share. The total sale was $4.2 million.

Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada. Seagen Inc has a market cap of $25.9 billion; its shares were traded at around $142.850000 with a P/E ratio of 43.29 and P/S ratio of

0 Views    insider    2021-04-10 01:15
Nasdaq up 7.5% for the year

The Dow Jones Industrial Average closed at 31,148.24 on Friday with a gain of 92.38 points or 0.30%. The S&P 500 closed at 3,886.83 for a gain of 15.09 points or 0.39%. The Nasdaq Composite closed at 13,856.30 for a gain of 78.55 points or 0.57%. The VIX Volatility Index was lower at 20.95 for a loss of 0.82 points or -3.77%.

For the week, the Nasdaq gained 6.1%, the S&P 500 gained 4.7% and the Dow Jones gained 3.9%. For the year, the S&P 500 has a gain of 3.5%, the Nasdaq is up 7.5% and the Dow Jones

105 Views    Julie Young    2021-02-05 22:06
Company recognized for product approvals and scientific achievements

Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year-to-date, far outpacing the Nasdaq Biotechnology Index, which has climbed about 28% since the beginning of the year. Seagen now trades at $182 per share and has been as high as $215.

In its 24-year history, Seagen (formerly Seattle Genetics) has gone from a small start-up pressed for cash to a recognized leader in the rapidly growing area of targeted cancer medicines. With a market cap of

74 Views    Barry Cohen    2020-12-31 15:25
Suitors like Amgen, Pfizer, Sanofi are likely eyeing mid-size companies that are more affordable

The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiotech. The publication enlisted the help of Jeffries' Jared Holtz to compile a list of the 10 top industry takeover targets.

Holtz thinks that most deals going forward will be those of the mid-size variety. That rules out several companies that were once the most highly coveted but have since become too expensive, including Seattle Genetics Inc. (SGEN), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals Inc. (REGN).

Holz thinks

302 Views    Barry Cohen    2020-10-19 21:37
Biotech's shares up more than 140% in past year

Even though it’s not expected to be profitable until 2022, Seattle Genetics Inc. (SGEN) continues to generate strong investor backing. Shares of the 27-year-old Bothell, Washington-based biotech have shot up more than 140% in the past year.

The stock climbed about $15 this week alone as the company beat earnings estimates and reported sterling sales of the new bladder cancer treatment Padcev, which the company co-developed with Astellas Pharma Inc. (TSE:4503) of Japan

Padcev just received approval in mid-December. Yet, in the first quarter, the newcomer recorded sales of more than $34 million. FiercePharma reported that number surprised JPMorgan analyst

80 Views    Barry Cohen    2020-05-07 20:42
Needham analyst raises target price after promising results of drug trial

Seattle Genetics Inc. (SGEN) CEO Clay Siegall called new data from the study of the company’s breast cancer drug “stunning.” Based on the fresh information, Needham analyst Chad Messer raised his target price on Seattle Genetics by $9 to $130, according to an article in The Fly.

Messner’s expectations are in line with the 16 analysts offering 12-month price forecasts for the biotech company. They have a median target of $120, with a high estimate of $140 and a low estimate of $87. Seattle Genetics, currently trading at just over $112, is rated a buy.

The release of

138 Views    Barry Cohen    2019-12-12 21:57
Cancer treatments draw plenty of investor interest. Here are the top 5 oncology companies that I believe offer investors the largest opportunities

Cancer is a devastating ailment. While the oncology field has progressed in leaps and bounds over the past couple of decades, there are still many cancer types that come with few solutions and high mortality rates.

The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. By the year 2026, it is expected that the oncology market will be worth $126.9 billion. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy

302 Views    Joshua Rodriguez    2019-04-10 16:40
Competitive advantages are dynamic and can be positive, negative or stable

For some of us, corporate moats are static. But for the moat team at Morningstar (MORN), they are dynamic.

In the book “Why Moats Matter: The Morningstar Approach to Stock Investing,” contributor Stephen Ellis, the head of financial services equity research at Morningstar, wrote, “Moat ratings can tell you the width of a company’s current moat, but trend ratings tell you if that moat is holding up well, is getting even stronger, or is in danger of being filled in by a rampaging horde of invaders.”

Ellis, along with lead authors Heather Brilliant and Elizabeth Collins, argue that as corporations

354 Views    Robert Abbott    2019-03-27 21:54
The failure of ImmunoGen's antibody-drug conjugate in Phase III trials this week has investors wondering whether this particular approach to cancer treatment is viable long term

Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies.

The stock fell 50% on the news, but there may be wider implications here than a hit to a single company. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.

That statement isn’t coming from a scientific perspective, but from an investment and economic

129 Views    Matt Winkler    2019-03-06 17:22
Seattle Genetics tops the list

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors.

Eight gurus are invested in Seattle Genetics Inc. (SGEN). The biotech company develops therapies for the treatment of cancer. It has a market cap of $12.41 billion. Its revenue of $575.66 million has climbed 26.40% over a 10-year period.

The stock is trading with a price-book ratio of 8.97. As of Friday, the price of $78 is 2.25% below its 52-week high and 61.34% above its 52-week low. Over the last 10 years, it has returned a gain of 551%.

The company’s largest

118 Views    Tiziano Frateschi    2018-09-17 20:26
Guru real-time pick highlight

Baupost Group manager Seth Klarman (Trades, Portfolio) disclosed on Monday that he increased his stake in Atara Biotherapeutics Inc. (ATRA).

Trade details

Klarman invested in 895,000 shares of Atara for $39 per share. With this transaction, the manager expanded the portfolio 0.35%.


According to GuruFocus estimates, Klarman gained approximately 28% on the stock.


Company background

San Francisco-based Atara develops novel treatments for patients with cancer, autoimmune and viral diseases. GuruFocus ranks Atara’s financial strength 8 out of 10 as the company has

294 Views    James Li    2018-04-10 16:38
Seattle Genetics rises in premarket trading

The U.S. stock market indexes opened in green Monday. The S&P 500, the Nasdaq and the Dow Jones started the week with gains.

Shares of Seattle Genetics Inc. (SGEN) traded more than 5% higher on the back of the company's announcement the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Adcetris (brentuximab vedotin) in combinationn with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. In June, the company announced positive results for the phase III ECHELON-1 clinical trial. The results of the full study will be announced at the American Society of

69 Views    Omar Venerio    2017-10-02 18:03
These stocks had great 12-month performances

According to GuruFocus' All-in-One Guru Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.

ONEOK Partners LPÂ (OKS) with a market cap of $14.88 billion has outperformed the S&P500 Index by 88.5% over the last 12 months.

ONEOK is engaged in the gathering, processing, storage and transportation of natural gas in the United States.

Its shares are trading with a price-book (P/B) ratio of 2.48. According to the DCF calculator, the company looks overpriced by 280% at

423 Views    Tiziano Frateschi    2017-02-21 21:01
The largest insiders' buys and sales of the week

The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$200,000+” duration to October 2016 and November 2016 and All Insider Sales to “$5,000,000+”.

According to the above filters, the following are recent buys and sells from company insiders in the past week.

Carl Icahn (Trades, Portfolio), 10% owner of Herbalife Ltd. (HLF), bought 1,832,402 shares for $54.70 per share on Nov. 3. Since then, the stock price has

1450 Views    Tiziano Frateschi    2016-11-05 15:20
Insiders buying the biggest bundles of their companies' stock

The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "March 2016."

According to the above filters, the following are recent buys from company insiders in the past week.

On March 14, GlaxoSmithKline PLC (GSK), a 10% owner of Theravance Biopharma Inc. (TBPH), bought 1,301,015 shares of the company that has an insider ownership of 0.59% and institutional ownership of 73.40%.

The company has ROE of -69.97% and ROA of -60.35%.

The company’s

731 Views    Tiziano Frateschi    2016-03-18 21:00

Headlines Total 136
  • 1
  • 2

2021-04-30 $ 143.76 (3.25%)
2021-04-29 $ 139.23 (-3.66%)
2021-04-22 $ 143.65 (-2.6%)
2021-04-20 $ 144.76 (0.52%)
2021-04-15 $ 149.64 (3.77%)
2021-04-12 $ 140.72 (-1.49%)
2021-04-10 $ 142.85 (-1.12%)
2021-03-29 $ 139.93 (0.19%)
2021-03-15 $ 151.67 (0.62%)
2021-03-06 $ 149.35 (2.68%)
2021-03-05 $ 149.35 (2.68%)
2021-02-19 $ 157.75 (-0.55%)
2021-02-17 $ 158.83 (-0.32%)
2021-02-15 $ 165.84 (%)
2021-02-12 $ 165.84 (-3.59%)
2021-02-11 $ 172.02 (1.58%)
2021-02-10 $ 169.35 (-3.63%)
2021-02-08 $ 177.15 (-7.06%)
2021-02-06 $ 190.61 (15.23%)
2021-02-05 $ 190.61 (15.23%)
2021-02-04 $ 165.42 (1.42%)
2021-01-29 $ 164.27 (1.05%)
2021-01-16 $ 185.75 (5.62%)
2021-01-09 $ 177.66 (0.74%)
2021-01-05 $ 169 (0.34%)
2020-12-31 $ 175.14 (-4.66%)
2020-12-19 $ 201.15 (1.63%)
2020-12-17 $ 197.7 (0.86%)
2020-12-14 $ 193.59 (1.26%)
2020-12-09 $ 184.46 (2.91%)
2020-12-05 $ 179.23 (-0.52%)
2020-12-03 $ 180.16 (1.76%)
2020-11-10 $ 168.46 (-2.98%)
2020-11-07 $ 173.63 (-4.47%)
2020-11-05 $ 180 (6.82%)
2020-10-30 $ 166.8 (-13.28%)
2020-10-29 $ 192.34 (-1.29%)
2020-10-22 $ 200.66 (1.49%)
2020-10-21 $ 197.71 (-0.16%)
2020-10-19 $ 198.22 (-1.35%)
2020-10-13 $ 211.93 (2.94%)
2020-10-07 $ 201.03 (0.71%)
2020-10-02 $ 193.08 (-2.43%)
2020-09-24 $ 179.43 (0.09%)
2020-09-23 $ 179.27 (-1.47%)
2020-09-18 $ 180.94 (3.01%)
2020-09-16 $ 176.62 (1%)
2020-09-15 $ 174.87 (1.79%)
2020-09-14 $ 171.79 (14.55%)
2020-09-03 $ 156.07 (1.57%)
2020-08-28 $ 153.66 (-0.29%)
2020-08-13 $ 160.14 (0.85%)
2020-08-06 $ 162.59 (-1.5%)
2020-07-31 $ 166.27 (-2.85%)
2020-07-30 $ 171.14 (1.62%)
2020-07-23 $ 172.9 (-2.22%)
2020-07-10 $ 174.35 (-3.76%)
2020-07-06 $ 170.45 (0.84%)
2020-06-23 $ 170.92 (0.59%)
2020-06-22 $ 170.92 (0.59%)
2020-06-10 $ 156.7 (5.21%)
2020-05-15 $ 160.33 (0.15%)
2020-05-14 $ 160.09 (1.43%)
2020-05-13 $ 157.84 (-2.43%)
2020-05-12 $ 161.77 (0.5%)
2020-05-11 $ 160.96 (2.09%)
2020-05-09 $ 157.67 (-3.42%)
2020-05-08 $ 157.67 (-3.42%)
2020-05-07 $ 163.26 (-0.84%)
Total 136
  • 1
  • 2